MAKO Surgical (MAKO), a medical device company, markets its advanced robotic arm solution, joint specific applications for the knee and hip, and orthopedic implants for orthopedic procedures in the United States and internationally.

The company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient specific osteoarthritic disease. It also provides robotic arm interactive orthopedic system (RIO) consisting of a tactile robotic arm utilizing an integrated bone cutting instrument; and a patient specific visualization component, which offers pre-operative and intra-operative guidance to the orthopedic surgeon, enabling tissue sparing bone removal, and accurate implant insertion and alignment.

In addition, the company offers MAKOplasty partial knee arthroplasty (PKA) products that enable resurfacing of one or two specific diseased compartments of the joint, preserving more soft tissue and healthy bone of the knee; and MAKOplasty Total Hip Arthroplasty, a surgical solution that enables orthopedic surgeons to perform total hip arthroplasty.

Further, it provides RESTORIS onlay knee implant system for patients who lack tibia sclerotic bone beds; RESTORIS MCK unicompartmental and bicompartmental knee implant system to support the tissue and bone sparing goals of MAKOplasty PKA; and RESTORIS family of hip implant systems.

The company markets and sells its products through direct sales force, as well as through independent orthopedic product agents and distributors. MAKO Surgical Corp. was founded in 2004 and is headquartered in Fort Lauderdale, Florida.

Sources: company, OxBridge Research, Daily Stock Deals